IONSIonis Pharmaceuticals, Inc.

Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares trading at a premium rather than as an obvious bargain. Ionis Pharmaceuticals has delivered a 47.3% return over the past three years, which puts recent pricing in focus for anyone considering new capital at work. The recent securities investigation following the Wainua trial setback may weigh on risk perceptions, while any renewed...

Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past 3 months. That mixed pattern sets the stage for a closer look. See our latest analysis for Ionis Pharmaceuticals. Over the past year, Ionis Pharmaceuticals has combined weak recent momentum with stronger long term returns. The share price is up 4.6% over 30 days but down 22.9% over 3 months, while the 1 year total shareholder return is...

A drug that didn't meet expectations in a trial is to blame.

Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.

Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

Ionis Pharmaceuticals Inc (IONS) reports a 56% year-over-year revenue increase, driven by strong product sales and strategic pipeline developments.

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch progress for TRYNGOLZA in severe hypertriglyceridemia. Chief Executive Officer Brett Monia said the

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +51.69% and +40.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design. This setback removes a late-stage cardiovascular candidate from Ionis’ pipeline spotlight and shifts attention toward earlier-stage RNA-targeted programs such as ION337 for Dravet syndrome. We’ll now examine...

Ionis Pharmaceuticals (IONS) is back in focus after mixed R&D news, with the high profile CARDIO-TTRansform trial for eplontersen missing its primary endpoint, while the new ASCEND study for Dravet syndrome candidate ION337 has begun dosing. See our latest analysis for Ionis Pharmaceuticals. The recent CARDIO-TTRansform setback appears to align with a sharp loss of momentum in Ionis Pharmaceuticals’ share price, which is down 28.83% over the past 30 days and 32.21% year to date, even as the...

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential. On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares. On July 9, Raymond James raised the firm’s price target […]

IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.

Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.